ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis

Stock Information for ChromaDex Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ChromaDex Corporation

ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®
ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured(TM) Transparency Program
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.